Could Prostate Cancer Drugs Help Fight COVID Infections?

Prostate cancer drug shows promise against COVID

Host: 

Welcome to Health Lab, your destination for news and stories about the future of healthcare. Today: Could Prostate Cancer Drugs Help Fight COVID Infections? One prostate cancer drug shows promise against COVID.

At the outset of the COVID pandemic, men appeared to suffer higher rates of severe illness and death, leading researchers to suspect a link between androgen receptors—which bind to hormones like testosterone--and SARS-CoV-2 viral infection.

This observation spurred Michigan Medicine researchers to look into a drug in development to treat prostate cancer called proxalutamide, which works by blocking an enzyme called TMPRSS2 (transmembrane protease, serine 2) that is regulated by androgen receptors, as a potential therapeutic for COVID.

“We were already studying TMPRSS2 as part of the key gene driver of over 50 percent of prostate cancer, so it made sense to look at it as TMPRSS2 is an important host factor for SARS-CoV-2 to enter cells in the lung,” said Arul Chinnaiyan, M.D., Ph.D., director of the Michigan Center for Translational Pathology and the S.P. Hicks Endowed Professor of Pathology.

Chinnaiyan, co-principal investigator Jonathan Sexton, Ph.D., assistant professor of Internal Medicine at the University of Michigan Medical School and Assistant professor of medicinal chemistry in the College of Pharmacy and their team recently published their study in the Proceedings of the National Academy of Sciences.

The team added proxalutamide to cells infected with SARS-CoV-2 to monitor its ability to block viral entry.

The compound works by binding to androgen receptors, inhibiting levels of TMPRSS2 and ACE2, and blocking infection.

What’s more, proxalutamide worked better than other prostate cancer drugs against multiple variants of SARS-CoV-2 due to its ability to break down the androgen receptor.

Additionally, proxalutamide, when combined with FDA-approved COVID drug remdesivir, blocked infection by 100%.

“This discovery underscores the utility of testing existing drugs for new applications that can be rapidly evaluated in humans to shorten the timeline from discovery to clinical evaluation," said Sexton, who is also director of the U-M Center for Drug Repurposing.

Buoyed by their in vitro results, the team looked to see whether the compound could stop the so-called cytokine storm, or severe inflammatory response, caused by SARS-CoV-2 infection.

Using a mouse model, they demonstrated that the drug reduced inflammation and cell death in the lungs of mice and reduced mortality.

Said Chinnaiyan, “The thought is proxalutamide could work as a combined therapy with remdesivir, hitting the virus from multiple angles, much as combination therapy works so well for HIV infection.”

The drug is currently in phase 3 clinical trials for prostate cancer and early clinical trials for COVID.

For more on this story and others like it, visit michiganmedicine.org/health-lab. Health Lab is a part of the Michigan Medicine Podcast Network and is produced by the Michigan Medicine Department of Communication. You can subscribe to Health Lab wherever you listen to podcasts.


More Articles About:

covid drugs Prostate Cancer Pathology Medical School Michigan Medicine podcast
Health Lab Podcast in brackets with a background with a dark blue translucent layers over cells

Health Lab Podcast

Listen to more Health Lab podcasts - a part of the Michigan Medicine Podcast Network.

Featured News & Stories

Blue and yellow illustration of DNA helix
Health Lab

New anti-cancer strategy shows promise in preclinical studies

New cancer therapeutic strategy rewires protein interactions to improve efficacy and reduce potential side effects.
Rachel Upjohn Building groundbreaking ceremony
News Release

How U-M helped bring depression out of the darkness

The history of the founding of the Eisenberg Family Depression Center at the University of Michigan, the nation's first center focused on research, community outreach and stigma reduction in depression and bipolar disorder.
Minding memory above a microphone on a blue background
Minding Memory

Giving Voice to Lived Experience in Dementia Research

In this episode, Lauren & Matt talk to Brenda Roberts and Steven Barbieri from the National Council of Dementia Minds. The National Council of Dementia Minds is the first national not-for-profit organization founded and governed by people living with dementia. Its work focuses on education, advocacy, peer support, and changing public perception of what it means to live with dementia. Brenda and Steven talk about the National Council of Dementia Minds, the importance of peer support and education for people living with dementia. They focus on how better understanding the lived experiences of people living with dementia can help shape research, policy, and advocacy.
Group of men smiling in a field
News Release

How have diagnostic and treatment decisions for prostate cancer changed in recent years?

An analysis of United States data reveals a broad shift away from overtreatment of low-risk prostate cancer. The analysis by University of Michigan Rogel Cancer Center researchers, indicates a shift toward surveillance in response to concerns of overdiagnosis and overtreatment that have hindered screening in the recent past.
UMich Med Mosaic on blue background with colorful geometric shapes
UMich Med Mosaic

Beyond the White Coat: Disability, Neurodiversity and Advocacy in Medical School

In this episode of UMich Med Mosaic, host Mackenzie Kay sits down with medical students Jill Maudlin, Sarah Renberg and Bella Johnson to discuss their experiences as disabled and neurodivergent trainees at the University of Michigan Medical School. They reflect on the personal journeys that led them to medicine, the challenges and strengths that accompany living with disabilities and chronic health conditions and the importance of representation within the medical profession. The conversation explores how disability shapes their approaches to patient care, advocacy and teamwork, as well as the role of the Medical Students for Disability Health Advocacy (MSDHA) organization in creating community and advancing accessibility initiatives. They also discuss Michigan’s accommodations in medical education, efforts to improve disability-related curriculum content and the importance of building a culture where disabled and neurodivergent students can thrive.
UMich Med Mosaic on blue background with colorful geometric shapes
UMich Med Mosaic

Beyond the White Coat: The Med Student Tradition Behind Michigan’s Smoker

In this episode of UMich Med Mosaic, host Mackenzie Kay sits down with graduating student Gareema Agarwal and MD/PhD student Mark Adame to explore the history, traditions and behind-the-scenes work that bring the University of Michigan Medical School’s annual Smoker production to life. As outgoing Smoker Czars, they share how they became involved in the beloved student-run comedy musical, the process of writing, casting and producing the show, and the challenges of balancing a major creative undertaking during their medical training.